The paradox of immune cell populations and transcription factors

Can you have your immune cake and eat it?

March 23, 2022
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021

What happens when genomics, KRAS, and IO converge in lung cancer?

Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?

February 2, 2021

Hot Topics: What we learned from SITC20 about an emerging class of oncology agents

A look at several different innate immune system approaches

November 18, 2020

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020

Under the Radar

An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy

February 28, 2020

A STING in the long tail?

What can we learn from recent trial data exploring a STING agonist in combination with anti-PD-1 in advanced solid tumors including TNBC & melanoma?

August 2, 2019

Window through the world of early STING agonist development

Targeting STING in cancer with a systemic small molecule approach? What's the story?

February 22, 2019

Can next generation STING agonism make a difference?

What does a next generation STING agonist look like and what issues is it attempting to address?

February 21, 2019

Insights on the STING agonist landscape

An in-depth look at the growing STING R&D landscape in oncology

February 20, 2019

New developments in tumour immunology and immunotherapy

Highlights from the AACR special conference on tumour immunology and immunotherapy

December 1, 2018

What can we learn from early IO trials?

There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.

November 16, 2018

ESMO18 Preview 1 Late Breakers What To Watch Out For

ESMO18 Preview 1 - Late Breaking Abstracts to watch out for

September 26, 2018

The STING and Metastasis Controversy Reignited

Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.

January 29, 2018

Can STING agonists promote cancer metastasis?

Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.

January 23, 2018

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017

Overcoming Cancer Immunotherapy Resistance

How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.

April 17, 2017

What we learnt at AACR about Aduro ADU-S100

Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...

May 25, 2016

Tom Gajewski takes the STING out of Cancer

Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.

May 13, 2015

What is STING and why does it matter in cancer immunotherapy?

Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.

March 30, 2015